0000315066-17-002955.txt : 20171214 0000315066-17-002955.hdr.sgml : 20171214 20171214150510 ACCESSION NUMBER: 0000315066-17-002955 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171212 FILED AS OF DATE: 20171214 DATE AS OF CHANGE: 20171214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 171255972 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2017-12-12 1 0001714899 Denali Therapeutics Inc. DNLI 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 0 1 See Remark 1 Common Stock 2017-12-12 4 C 0 2188869 A 2841896 I Impresa Fund III Limited Partnership Common Stock 2017-12-12 4 C 0 45035 A 2886931 I Impresa Fund III Limited Partnership Common Stock 2017-12-12 4 C 0 112590 A 2999521 I Impresa Fund III Limited Partnership Common Stock 2017-12-12 4 C 0 808013 A 1049072 I F-Prime Capital Partners Healthcare Fund IV LP Common Stock 2017-12-12 4 C 0 16624 A 1065696 I F-Prime Capital Partners Healthcare Fund IV LP Common Stock 2017-12-12 4 C 0 41561 A 1107257 I F-Prime Capital Partners Healthcare Fund IV LP Common Stock 2017-12-12 4 C 0 24240 A 31471 I F-Prime Capital Partners Healthcare Advisors Fund IV LP Common Stock 2017-12-12 4 C 0 498 A 31969 I F-Prime Capital Partners Healthcare Advisors Fund IV LP Common Stock 2017-12-12 4 C 0 1246 A 33215 I F-Prime Capital Partners Healthcare Advisors Fund IV LP Common Stock 750001 I F-Prime Inc. Series A-1 Convertible Preferred Stock 2017-12-12 4 C 0 2188869 D Common Stock 2188869 0 I Impresa Fund III Limited Partnership Series A-1 Convertible Preferred Stock 2017-12-12 4 C 0 808013 D Common Stock 808013 0 I F-Prime Capital Partners Healthcare Fund IV LP Series A-1 Convertible Preferred Stock 2017-12-12 4 C 0 24240 D Common Stock 24240 0 I F-Prime Capital Partners Healthcare Advisors Fund IV LP Series A-2 Convertible Preferred Stock 2017-12-12 4 C 0 45035 D Common Stock 45035 0 I Impresa Fund III Limited Partnership Series A-2 Convertible Preferred Stock 2017-12-12 4 C 0 16624 D Common Stock 16624 0 I F-Prime Capital Partners Healthcare Fund IV LP Series A-2 Convertible Preferred Stock 2017-12-12 4 C 0 498 D Common Stock 498 0 I F-Prime Capital Partners Healthcare Advisors Fund IV LP Series B-1 Convertible Preferred Stock 2017-12-12 4 C 0 112590 D Common Stock 112590 0 I Impresa Fund III Limited Partnership Series B-1 Convertible Preferred Stock 2017-12-12 4 C 0 41561 D Common Stock 41561 0 I F-Prime Capital Partners Healthcare Fund IV LP Series B-1 Convertible Preferred Stock 2017-12-12 4 C 0 1246 D Common Stock 1246 0 I F-Prime Capital Partners Healthcare Advisors Fund IV LP On December 12, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund IV LP is F-Prime Capital Partners Healthcare Advisors Fund IV LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2017-12-14